Thompson Davis & Co’s Novo Nordisk NVO Stock Holding History

Thompson Davis & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410K	Buy	+8,550	New	+$367K	0.25%	78
2024 Q4	–	Sell	-3,530	Closed	-$420K	–	142
2024 Q3	$420K	Sell	3,530 -2,750	-44%	-$367K	0.31%	56
2024 Q2	$896K	Hold	6,280	–	–	0.78%	21
2024 Q1	$806K	Buy	6,280 +780	+14%	+$92.9K	0.55%	20
2023 Q4	$569K	Buy	5,500 +2,700	+96%	+$267K	0.48%	24
2023 Q3	$255K	Buy	+2,800	New	+$247K	0.31%	57
2016 Q4	–	Sell	-874	Closed	-$18K	–	1178
2016 Q3	$18K	Sell	874 -214	-20%	-$5.31K	0.03%	514
2016 Q2	$29K	Hold	1,088	–	–	0.05%	355
2016 Q1	$29K	Buy	1,088 +578	+113%	+$15.5K	0.04%	343
2015 Q4	$15K	Sell	510 -158	-24%	-$4.37K	0.02%	552
2015 Q3	$18K	Hold	668	–	–	0.03%	498
2015 Q2	$18K	Buy	668 +134	+25%	+$3.77K	0.02%	573
2015 Q1	$14K	Hold	534	–	–	0.02%	647
2014 Q4	$11K	Sell	534 -284	-35%	-$6.34K	0.01%	713
2014 Q3	$19K	Buy	+818	New	+$18.8K	0.02%	477

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Thompson Davis & Co's NVO Position: Q2 2026 in Review

Thompson Davis & Co opened a new position in Novo Nordisk (NVO) in Q2 2026: 8,550 shares worth $410K. The stake represents 0.25% of the portfolio and ranks #78 among its holdings. This is a return to the name: Thompson Davis & Co previously reported a position in NVO as recently as Q3 2024.

Thompson Davis & Co first reported a position in NVO in Q3 2014 and has held it in 15 quarters since. The position peaked at $896K in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Thompson Davis & Co held 8,550 shares of Novo Nordisk worth $410K as of Q2 2026.
Novo Nordisk was a new Thompson Davis & Co position in Q2 2026.
Novo Nordisk made up 0.25% of Thompson Davis & Co's portfolio in Q2 2026, its #78 holding.
Thompson Davis & Co first reported a position in Novo Nordisk in Q3 2014 and has held it in 15 quarters since.
Thompson Davis & Co's Novo Nordisk position peaked at $896K in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.